Washington Osorio

Washington Osorio

Auto-generated profile, based on publicly available information

Washington Osorio

Servicio de nefrología, Hospital de Especialidades Fuerzas Armadas N1, Quito

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 March 2025 in Revista de la Sociedad Ecuatoriana de Nefrología, Diálisis y Trasplante
Verified
Journal Article
Open access
PDF file
DGDavid Garrido
David Garrido
OSOmar Seminario
Omar Seminario
JSJuan Santacruz
Juan Santacruz
EMEvelyn Moreira
Evelyn Moreira
RLRosalina Lituma
Rosalina Lituma
JHJorge Huertas
Jorge Huertas
Introduction: Multiple myeloma (MM) is a hematological malignancy that often causes kidney failure, affecting more than 50% of MM patients. Kidney damage in MM is primarily due to cast nephropathy, light chain deposition disease, and amyloidosis. However, there are no data on MM patients undergoing hemodialysis in Ecuador. This study aims to report the prevalence of MM in the country's hemodialysis units. Methods: This observational, descriptive, cross-sectional, multicenter study evaluated the prevalence of MM in hemodialysis patients in Ecuador. A survey was distributed to 23 nephrologists, collecting data on the total number of hemodialysis patients and those diagnosed with MM. Prevalence was calculated using the formula: Prevalence = (MM patients / Total hemodialysis patients) × 1000. Data were analyzed using nonparametric methods in R v4.3.2, with 99% confidence intervals. Results: were diagnosed with MM, yielding a prevalence of 1.1% (95% CI: 0.7% to 1.6%), or 11.3 cases per 1000 hemodialysis patients. The number of MM cases varied by city, with the highest number reported in Portoviejo (10 cases) and none in Riobamba. Conclusion: The prevalence of MM in Ecuador is consistent with international reports, with similar findings in the United States (1.0%), Nigeria (0.81%), and other Latin American countries. These findings highlight the need for a national registry to better understand the needs of MM patients on hemodialysis.

8 September 2022 in Revista de la Sociedad Ecuatoriana de Nefrología, Diálisis y Trasplante
Verified
Journal Article
Open access
PDF file
Jorge Rico FontalvoJorge Rico Fontalvo
Jorge Rico Fontalvo
RDRodrigo Daza-Arnedo
Rodrigo Daza-Arnedo
TYTomas Rodriguez Yanez
Tomas Rodriguez Yanez
WOWashington Osorio
Washington Osorio
BSBeatriz Suarez-Romero
Beatriz Suarez-Romero
JGJuan Camilo Gutierrez
Juan Camilo Gutierrez
Introduction: Chronic kidney disease associated with obesity (CKD-WO) has increased in prevalence in recent decades. It is characterized by excess adipocytic hormonal imbalances (adipokines), deregulation of the energy balance system, and imbalances in metabolic homeostasis. Purpose of the review: The objective is to outline the different pathophysiological mechanisms' role in developing functional or anatomical kidney disease in obese patients. We look for updated reports that include the best survival results for patients with CKD. Recent findings: We currently know that CKD-WO has a chronic pro-inflammatory behavior. Obesity and overweight are associated with hemodynamic, structural, and histopathological alterations in the kidney and metabolic and biochemical alterations that predispose to kidney disease, even when renal function and conventional tests are normal. Conclusions: We classify CKD-WO in Type 1: Obesity and potentially reversible functional alterations. Type 2: Obesity and potentially non-reversible histopathological structural alterations (includes glomerulopathy associated with obesity and focal segmental glomerulosclerosis). Type 3: Obesity-related to chronic diseases (diabetes, hypertension, pulmonary hypertension, heart failure). Type 4: Obesity in the patient with renal function replacement therapy.

24 January 2024 in Revista Colombiana de Nefrología
Verified
Journal Article
Open access
PDF file
ABAndré Benítez
André Benítez
DGDavid Garrido
David Garrido
ABAndrea Banegas
Andrea Banegas
MMMaría Belen Mena
María Belen Mena
WOWashington Osorio
Washington Osorio
LSLiseth Sierra-Torres
Liseth Sierra-Torres
Introduction: During the last decades the use of erythropoiesis stimulating agents has significantly diminished the prevalence of anemia in patients receiving chronic hemodialysis. Currently, residing at higher altitudes is associated with higher levels of endogenous erythropoietin. Objective: This study aims to analyze how residing at higher altitudes influences the requirements of exogenous erythropoietin in patients receiving hemodialysis as renal replacement therapy. Methodology: Descriptive observational cross-section, including adult patients from three Ecuadorian centers, receiving chronic hemodialysis, between January and June 2020. Patients were classified into two groups regarding the altitude of residence: those living at low-lying regions (2000 masl, Quito). Results: We included 580 patients, 45.5% in the high-altitude group and 54.5% at low-lying regions. Median exogenous erythropoietin dose was higher in low-lying regions (22000 international units) versus high altitude (17333.3 international units) (P=0.00003) and the proportion of patients without erythropoietin requirement was higher in high altitude (21.6%), compared to low regions (1.0%) (P<0.01). The multivariate analysis associated residing in low regions (HR 58.9, P<0.01), age (HR 0.98, P=0.03) and Kt/V (HR 38.5, P<0.01) with higher exogenous erythropoietin requirements. Additionally, among patients who required erythropoietin, residing in lower altitudes was linked with a need for exogenous erythropoietin doses exceeding 15000 international units per week (HR 1.92, P=0.001). Conclusion: In Ecuadorian patients receiving hemodialysis, living at high altitude is associated with a reduced requirement of exogenous erythropoietin compared with those patients residing in low-lying regions.

3 February 2024 in Revista de la Sociedad Ecuatoriana de Nefrología, Diálisis y Trasplante
Verified
Journal Article
Open access
PDF file
WRWilmer Stalin Sanango Reinoso
Wilmer Stalin Sanango Reinoso
WCWashington Xavier Osorio Chuquitarco
Washington Xavier Osorio Chuquitarco
STSantiago David Silva Tobar
Santiago David Silva Tobar
OOOctavio José Salgado Ordoñez
Octavio José Salgado Ordoñez
Introduction: Aristolochic acids contain a carboxylic nitro phenanthrene group and can be found in medicinal herbs of the genus Aristolochia. Their nephrotoxicity has been confirmed in endemic geographic areas such as the Balkans of Europe and the Central American region. The clinical findings consist of tubulointerstitial nephropathy and generally go unnoticed until the advanced stages of chronic kidney disease. Objective of the review: The aim is to describe the main pathophysiological aspects and establish diagnostic and treatment criteria in patients with Aristolochic Acid Nephropathy. Essential points of the review: About 180 types of aristolochic acids (AAs) have been discovered, the most critical types AAΙ, AAΙΙ, AAΙΙΙa (AA C) and AAΙVa (AA D), which are differentiated according to the position of their hydroxyl radical (OH), hydrogen (H) and methoxyl (OCH3). AA-induced nephropathy occurs through at least five pathways that associate the depletion of intracellular glutathione, cellular damage due to induction of cell apoptosis, direct damage to the endoplasmic reticulum, and mitochondrial damage. This produces atrophic tubular injury and interstitial fibrosis; the metabolite has a bladder neoplastic effect. Conclusion: The incidence of aristolochic acid nephropathy is probably much higher than initially thought, and its existence should be considered in patients who present with chronic kidney disease with a tubulo-interstitial clinical pattern.

15 August 2023 in Revista de la Sociedad Ecuatoriana de Nefrología, Diálisis y Trasplante
Verified
Journal Article
Open access
PDF file
MBMarcela Valladares Benítez
Marcela Valladares Benítez
GQGabriela Bonilla Q.
Gabriela Bonilla Q.
WCWashington Xavier Osorio Chuquitarco
Washington Xavier Osorio Chuquitarco
MRMaría Fernanda Rivadeneira
María Fernanda Rivadeneira
DRDoris Yvonne Almeida Rivera
Doris Yvonne Almeida Rivera
Introducción: El acceso de adultos mayores a programas de hemodiálisis es cada vez mas frecuente. El objetivo de este estudio fue determinar la sobrevida de los adultos mayores con Enfermedad Renal Crónica (ERC) estadio 5 en Hemodiálisis, posterior a 5 años de seguimiento, en relación con la desigualdad social, y las características clínicas, bioquímicas y funcionales de la población estudiada. Métodos: El presente estudio observacional, analítico, de fuente retrospectiva, se realizó en el Centro Nefrológico CLINEF Norte, en Quito, Ecuador, en el período 2007-2012. Se incluyeron pacientes >64 años, con ERC 5-d. Se registraron variables clínicas, nutricionales, economicas, sociodemográficas, mortalidad y sobrevida global (SG). La muestra fue no probabilística. Se midió sobrevida a los 5 años con Kaplan-Meier y se analizó la asociación entre las variables. Resultados: Se analizan 71 casos, con edad de 70.7 ± 6.6 años, 64.8 % hombres, 49.3 % con ingreso < 530 dólares. La SG a los 5 años fue de 48.9 %. Las variables que se asociaron significativamente con la SG fueron: sexo masculino (SG 49.0 ± 2.4 meses, P=0.010), ausencia de ECV con SG 45.3 ± 2.4 meses, P=0.010), albúmina > 3.51 g/dl (SG 49.7 ± 2.9 meses, P =0.009), Karnofsky > 80 ( SG 52.7 ± 2.2 meses, P=0.002). El sexo femenino y antecedente de ECV presentaron un HR estadísticamente significativo (HR 2.29, IC 95% 1.18 -4.43; HR 2.67, IC 95% 1.21-5.88). Al ajustar por ingreso económico bajo, junto al sexo femenino y albúmina baja, mantuvieron su asociación (HR 2.21, IC 95% 1.01-4.82), (P=0.044). Conclusión: El estado nutricional y la valoración funcional fueron los principales factores asociados a mayor sobrevida del adulto mayor en hemodiálisis. En un subanalisis se demostró que las mujeres con ingreso económico bajo tienen menor supervivencia.

28 February 2022 in Revista de la Sociedad Ecuatoriana de Nefrología, Diálisis y Trasplante
Verified
Journal Article
Open access
PDF file
HAHarold Alvarez
Harold Alvarez
WOWashington Osorio
Washington Osorio
Introduction: The approach to the renal condition of older people requires diagnostic tools for this age group, which allow for discerning the renal condition between chronicity and senescence. This research aimed to analyze whether the HUGE scale is a companion tool to determine the existence of chronic kidney disease in older adult patients seen in outpatient clinics. Methods: This observational, analytical, and cross-sectional study was carried out in the Specialty Hospital of the Armed Forces No. 1 nephrology outpatient clinic from 2015 to 2018. Results: We included 285 patients. The prevalence of chronic kidney disease was higher in people older than 75 years (60.7%). With the HUGE formula, a lower proportion of chronic kidney disease was established in 37% of men and 60% of women (P = 0.002) than in the CKD-EPI formula (83% and 89%, respectively). The specificity achieved by the HUGE formula was higher than the CKD-EPI and MDRD formulas (97% vs. 80% vs. 79%, respectively), having the highest discriminative capacity (NPV 70%). Hyperuricemia and diabetes mellitus are associated with the development of chronic kidney disease. Conclusions: This research showed that the HUGE formula helps discern older adults with decreased glomerular filtration due to senescent aging in those with kidney disease. In addition, the HUGE formula is recommended as a complementary tool in the approach to chronic kidney disease in older adults.